Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024

Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally. Many small-cap biotech stocks are being held back by the Fed’s more restrictive stance on interest rates. But even some of the large-cap names with commercially available drugs that are household names are also underperforming the market. But “some” isn’t the same as “all.” In a stock picker’s market, you want to find the stocks that have a chance to outperform. One way to find thes ...